Genmab (GMAB) announces topline results for epcoritamab from Phase 3 Epcore dlbcl-1 trial in patients with relapsed/refractory diffuse; said study OS did not reach statistical significance; study demonstrated an overall survival of hr: 0.96
Reaction details (18:56)
- Notable downside seen in shares since they unhalted.
16 Jan 2026 - 18:31- Important- Source: Business Wire
Subscribe Now to Newsquawk
Click here for a 1 week free trial
Newsquawk provides audio news and commentary for over 15,000professional traders and brokers worldwide. Services include:
- Real-time audio coverage from 0630 to 2200 London time plus Asia-Pac 2200 to 1000 London time
- Teams of analysts covering equities, fixed income, FX, energy, and metals markets
- Real-time scrolling news service with instant analysis
- Daily and weekly pre-market research and calendars
- Video updates covering near-term key risk events & primary trading themes
- One-to-one chat with our expert analysts